Skip to main content
. 2003 Oct 20;2003(4):CD001332. doi: 10.1002/14651858.CD001332

Smith 1994.

Methods Multi‐centre, parallel‐group study
Participants 220 patients aged 18‐70
Interventions Tizanidine (2‐36mg) v. placebo
Outcomes Primary end‐points: Ashworth score, patient diaries (muscle spasm & clonus scores). Secondary end‐points: reflexes, clonus, spasms (assessed by physician), muscle power (MRC grade), walking time, ADL, global evaluation of efficacy
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk B ‐ Unclear